Lipid-based nanoparticles are highly versatile platforms with extensive therapeutic
applications. Despite rapid scientific advances in the past several decades, clinical …

Nearly 17.9 million people die every year from cardiovascular-related diseases, which
accounts for 31% of all deaths worldwide. Endogenous high-density lipoproteins (HDL) are …

Biomimetic synthetic high-density lipoproteins (sHDLs) are nanoparticles that mimic the
physical, chemical, and biological activity of endogenous HDL. A number of sHDL products …

Solid lipid nanoparticles (SLNs) play a crucial role in drug delivery, offering benefits such as
enhanced bioavailability, targeted distribution, and reduced toxicity. This article provides a …

Solid lipid nanoparticles (SLNs), as alternative colloidal carriers, have been used for the
sustained release of lipophilic drugs with poor water solubility. One of the most important …

Solid lipid nanoparticles (SLNs) were introduced two decades ago and represent a
replacement to the shortcomings of conventional colloidal carrier systems, such as …

This chapter presents a platform that outlines diverse lipid nanocarrier approaches intended
for various inflammatory diseases. It capitalizes on the rapidly evolving domain of lipid …

High density lipoproteins (HDLs) are dynamic natural nanoparticles best known for their role
in cholesterol transport and the inverse correlation that exists between blood HDL levels and …

Lipid nanoparticles (LNPs) have gained prominence as primary carriers for delivering a
diverse array of therapeutic agents. Biological products have achieved a solid presence in …

There has been a steady increase in the interest towards employing nanoliposomes as
colloidal drug delivery systems, particularly in the last few years. Their biocompatibility …